RT Journal Article
T1 Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition.
A1 Lin, Crystal
A1 Travis, Ruth C
A1 Appleby, Paul N
A1 Tipper, Sarah
A1 Weiderpass, Elisabete
A1 Chang-Claude, Jenny
A1 Gram, Inger T
A1 Kaaks, Rudolf
A1 Kiemeney, Lambertus A
A1 Ljungberg, Börje
A1 Tumino, Rosario
A1 Tjønneland, Anne
A1 Roswall, Nina
A1 Overvad, Kim
A1 Boutron-Ruault, Marie-Christine
A1 Manciniveri, Francesca Romana
A1 Severi, Gianluca
A1 Trichopoulou, Antonia
A1 Masala, Giovanna
A1 Sacerdote, Carlotta
A1 Agnoli, Claudia
A1 Panico, Salvatore
A1 Bueno-de-Mesquita, Bas
A1 Peeters, Petra H
A1 Salamanca-Fernández, Elena
A1 Chirlaque, Maria-Dolores
A1 Ardanaz, Eva
A1 Dorronsoro, Miren
A1 Menéndez, Virginia
A1 Luján-Barroso, Leila
A1 Liedberg, Fredrik
A1 Freisling, Heinz
A1 Gunter, Marc
A1 Aune, Dagfinn
A1 Cross, Amanda J
A1 Riboli, Elio
A1 Key, Timothy J
A1 Perez-Cornago, Aurora
K1 EPIC cohort
K1 IGF-I
K1 bladder cancer
K1 prospective
K1 urothelial cell carcinoma
AB Previous in vitro and case-control studies have found an association between the insulin-like growth factor (IGF)-axis and bladder cancer risk. Circulating concentrations of IGF-I have also been found to be associated with an increased risk of several cancer types; however, the relationship between pre-diagnostic circulating IGF-I concentrations and bladder cancer has never been studied prospectively. We investigated the association of pre-diagnostic plasma concentrations of IGF-I with risk of overall bladder cancer and urothelial cell carcinoma (UCC) in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 843 men and women diagnosed with bladder cancer between 1992 and 2005 were matched with 843 controls by recruitment centre, sex, age at recruitment, date of blood collection, duration of follow-up, time of day and fasting status at blood collection using an incidence density sampling protocol. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for smoking status. No association was found between pre-diagnostic circulating IGF-I concentration and overall bladder cancer risk (adjusted OR for highest versus lowest fourth: 0.91, 95% CI: 0.66-1.24, ptrend = 0.40) or UCC (n of cases = 776; 0.91, 0.65-1.26, ptrend = 0.40). There was no significant evidence of heterogeneity in the association of IGF-I with bladder cancer risk by tumour aggressiveness, sex, smoking status, or by time between blood collection and diagnosis (pheterogeneity > 0.05 for all). This first prospective study indicates no evidence of an association between plasma IGF-I concentrations and bladder cancer risk.
YR 2018
FD 2018-09-11
LK http://hdl.handle.net/10668/12673
UL http://hdl.handle.net/10668/12673
LA en
DS RISalud
RD Apr 7, 2025